Drug Profile
Estradiol/nomegestrol sequential
Alternative Names: E2/Nomac sequential; EMM 210066; Naemis; Nomac/E2 sequential; TX 45066Latest Information Update: 30 Jan 2019
Price :
$50
*
At a glance
- Originator Theramex SAM
- Developer Theramex
- Class Estradiol congeners; Estrenes; Hormonal contraceptives; Hormonal replacements; Pregnadienes; Progesterone congeners; Small molecules
- Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Menopausal syndrome
Most Recent Events
- 30 Jan 2019 Chemical structure information added
- 01 Feb 2018 Teva Women's Health was sold by Teva Pharmaceuticals to CVC Capital Partners, to create an international pharmaceutical company dedicated to Women’s Health named Theramex
- 06 Jan 2011 Theramex SAM has been acquired by Teva Pharmaceutical Industries